2020 American Transplant Congress
Sodium Zirconium Cyclosilicate Use in Solid Organ Transplant Recipients and its Effect on Potassium and Immunosuppression
*Purpose: Transplant recipients often suffer from hyperkalemia which can limit pharmacotherapy. The cause of hyperkalemia is often multifactorial including kidney dysfunction, calcineurin inhibitor use, and…2020 American Transplant Congress
Kidney Transplant Results Comparing Two Formulations of Prolonged-Release Tacrolimus: Paired Study of Kidney Donors
*Purpose: Although the formulations of prolonged-release tacrolimus (Advagraf® and Envarsus®) are effective after kidney transplantation in terms of efficacy and safety, no paired analysis has…2020 American Transplant Congress
Role of Tacrolimus Dose Adjustment at Discontinuation of Fluconazole in Liver Transplant
University of Virginia Health System, Charlottesville, VA
*Purpose: The purpose of this study was to characterize the effects of fluconazole (fluc) discontinuation on tacrolimus (tac) levels and the role of prophylactic dose…2020 American Transplant Congress
Metformin Improves Biomarkers of Calcineurin Inhibitor Related Nephrotoxicity
Department of Nephrology, Prince of Wales Hospital, Randwick, Australia
*Purpose: Calcineurin Inhibitors (CNIs) prevent transplant rejection but cause significant nephrotoxicity. Biomarkers of CNI nephrotoxicity could help drug dosing and improve long-term graft outcomes. As…2020 American Transplant Congress
A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus
*Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…2020 American Transplant Congress
Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…2020 American Transplant Congress
Acute Kidney Injury And Chronic Kidney Disease After Lung Transplantation: Incidence And Risk Factors In A Large Single-center Cohort
Lewis Katz School of Medicine, Temple University, Philadelphia, PA
*Purpose: Chronic kidney disease (CKD) is a common complication after lung transplant. The reported incidence in small studies varies ranges from10-90%. Furthermore, data on risk…2019 American Transplant Congress
Transcriptome Profiling Of Renal Transplant Biopsies With Acute Cellular Rejection From Patients On Calcineurin Inhibitor-based Or Cni-avoidance Immunosuppression
*Purpose: Despite their suboptimal toxicity profile, calcineurin-inhibitors (CNIs) remain the cornerstone of renal transplant immunosuppression. Previous efforts to completely eliminate CNIs failed, because CNI-avoidance protocols…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 16
- Next Page »